While Arena Pharmaceuticals (ARNA) and VIVUS (VVUS), makers of the obesity drugs Belviq and Qsymia, respectively, both garner a lot of attention on Fool.com, they also have attracted the attention of the short sellers. In this video, Motley Fool health-care analyst David Williamson talks about the "buy the run-up, short the launch" trend, and whether the short-sellers are right not to believe in these stocks.
S&P 500
5,970.81
+0.0%
+$0.44
DJI
42,427.74
-0.2%
-$91.90
NASDAQ
19,460.49
+0.3%
+$61.53
Bitcoin
104,631.00
-0.7%
-725.60
AAPL
$202.99
-0.1%
-$0.28
AMZN
$207.37
+0.8%
+$1.66
GOOG
$169.50
+1.1%
+$1.79
META
$687.21
+3.1%
+$20.36
MSFT
$464.20
+0.3%
+$1.23
NVDA
$141.94
+0.5%
+$0.72
TSLA
$333.21
-3.2%
-$11.06
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.